Extravasation GuideTissue injury risk of antineoplastic extravasation

Trabectedin

Trabectedina

Risk class

Vesicant

If it extravasates

Compress

Cold

References

Risk class: VesicantONS/ASCO 2025 (Table 1, p. 385); ESMO-EONS 2012 (Table 1, p. vii167); JSCN/JSMO/JASPO 2024 (Table 2)

Compress: coldONS/ASCO 2025 (text, p. 390)

Details by guideline

Risk class in extravasation

ONS/ASCO 2025Vesicant
Alkylating agents (DNA-binding)
Table 1, p. 385
ESMO-EONS 2012Vesicant
Vesicants › Non-DNA-binding compounds › Others
Table 1, p. vii167
JSCN/JSMO/JASPO 2024Vesicant
Table 2

Compress

ONS/ASCO 2025Cold compress
Strength/level: Conditional; very lowAlkylating agents per ONS/ASCO Table 1; oxaliplatin excluded because the same guideline indicates a warm compressalkylating agents, anthracyclines, and antimetabolites
text, p. 390

Brand names (ANVISA, Brazil) · DCB (Brazil)

DCB (Brazil)trabectedina (nº 9648)

Brand names (ANVISA, Brazil)YONDELIS

General recommendations of the guidelines

ONS/ASCO 2025Recommendation 1 · Strong; very low
Use antidotes, when one exists, for vesicants and irritants with vesicant properties, rather than no antidote.
Table 3, p. 388
ONS/ASCO 2025Recommendation 3 · Conditional; very low
Thermal compress (cold or warm depending on the agent) rather than no compress.
Table 3, p. 388
ONS/ASCO 2025Recommendation 4 · Conditional; very low
Compress for more than 24 hours rather than 24 hours or less.
Table 3, p. 388
ONS/ASCO 2025Recommendation 5 · Conditional; very low
Central line extravasation: surgical referral or escalation of care in addition to conservative management.
Table 3, p. 388
JSCN/JSMO/JASPO 2024CQ10a · Recommend (weak)
Cold compression (weak recommendation).
Table 1, CQ10a
JSCN/JSMO/JASPO 2024CQ10b · Not recommend (weak); D
Non-use of warm compresses (weak recommendation).
Table 1, CQ10b

Search another drug